JP2015193630A5 - - Google Patents

Download PDF

Info

Publication number
JP2015193630A5
JP2015193630A5 JP2015104213A JP2015104213A JP2015193630A5 JP 2015193630 A5 JP2015193630 A5 JP 2015193630A5 JP 2015104213 A JP2015104213 A JP 2015104213A JP 2015104213 A JP2015104213 A JP 2015104213A JP 2015193630 A5 JP2015193630 A5 JP 2015193630A5
Authority
JP
Japan
Prior art keywords
sodium salt
salt dihydrate
crystalline genistein
genistein sodium
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015104213A
Other languages
English (en)
Other versions
JP6067781B2 (ja
JP2015193630A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015193630A publication Critical patent/JP2015193630A/ja
Publication of JP2015193630A5 publication Critical patent/JP2015193630A5/ja
Application granted granted Critical
Publication of JP6067781B2 publication Critical patent/JP6067781B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (4)

  1. 治療有効量の結晶性ゲニステインナトリウム塩二水和物と、少なくとも１種の薬学的に許容されるキャリアとを含む治療用組成物であって、
    前記結晶性ゲニステインナトリウム塩二水和物が、６．０、７．１、１５．３および２５．０°２θ±０．２°２θにおけるピークと、３つのピーク２８．３、２８．６および２９．１°２θ±０．２°２θのうちの少なくとも２つとを有するＸＲＰＤパターンを特徴とする、治療用組成物。
  2. 治療有効量の結晶性ゲニステインナトリウム塩二水和物と、少なくとも１種の薬学的に許容されるキャリアとを含む治療用組成物であって、
    前記結晶性ゲニステインナトリウム塩二水和物が、６．０、７．１、１５．３、２５．０および２８．３°２θ±０．２°２θにおけるピークを有するＸＲＰＤパターンを特徴とする、治療用組成物。
  3. 癌を治療または予防するための、請求項１または２に記載の組成物。
  4. 以下の（ｉ）または（ｉｉ）の結晶性ゲニステインナトリウム塩二水和物：
    （ｉ）６．０、７．１、１５．３および２５．０°２θ±０．２°２θにおけるピークと、３つのピーク２８．３、２８．６および２９．１°２θ±０．２°２θのうちの少なくとも２つとを有するＸＲＰＤパターンを特徴とする、結晶性ゲニステインナトリウム塩二水和物；または
    （ｉｉ）６．０、７．１、１５．３、２５．０および２８．３°２θ±０．２°２θにおけるピークを有するＸＲＰＤパターンを特徴とする、結晶性ゲニステインナトリウム塩二水和物；
    であって、治療有効量の前記結晶性ゲニステインナトリウム塩二水和物を必要な患者に投与する工程を含む癌の治療方法において使用するための、結晶性ゲニステインナトリウム塩二水和物。
JP2015104213A 2008-12-11 2015-05-22 ゲニステインの結晶形 Expired - Fee Related JP6067781B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12177808P 2008-12-11 2008-12-11
US12178708P 2008-12-11 2008-12-11
US61/121,787 2008-12-11
US61/121,778 2008-12-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011540919A Division JP5898958B2 (ja) 2008-12-11 2009-12-11 ゲニステインの結晶形

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016247753A Division JP2017061566A (ja) 2008-12-11 2016-12-21 ゲニステインの結晶形

Publications (3)

Publication Number Publication Date
JP2015193630A JP2015193630A (ja) 2015-11-05
JP2015193630A5 true JP2015193630A5 (ja) 2016-01-28
JP6067781B2 JP6067781B2 (ja) 2017-01-25

Family

ID=42243089

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011540919A Expired - Fee Related JP5898958B2 (ja) 2008-12-11 2009-12-11 ゲニステインの結晶形
JP2015104213A Expired - Fee Related JP6067781B2 (ja) 2008-12-11 2015-05-22 ゲニステインの結晶形
JP2016247753A Pending JP2017061566A (ja) 2008-12-11 2016-12-21 ゲニステインの結晶形

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011540919A Expired - Fee Related JP5898958B2 (ja) 2008-12-11 2009-12-11 ゲニステインの結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016247753A Pending JP2017061566A (ja) 2008-12-11 2016-12-21 ゲニステインの結晶形

Country Status (12)

Country Link
US (2) US9012495B2 (ja)
EP (1) EP2373326B1 (ja)
JP (3) JP5898958B2 (ja)
KR (2) KR20110106355A (ja)
CN (2) CN102292097B (ja)
AU (1) AU2009324489B2 (ja)
BR (1) BRPI0923504A2 (ja)
CA (1) CA2746652C (ja)
HK (1) HK1164698A1 (ja)
IL (2) IL213473A (ja)
WO (1) WO2010068861A1 (ja)
ZA (1) ZA201105045B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2373326B1 (en) 2008-12-11 2016-03-09 Axcentua Pharmaceutucals AB Crystalline forms of genistein
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
WO2011104667A1 (en) * 2010-02-25 2011-09-01 Anthem Biosciences Private Limited Basic aminoacid salts of polyphenols
CN102442990B (zh) * 2010-10-12 2015-03-11 上海睿智化学研究有限公司 一种金雀异黄素烟酰胺共晶、其晶体及其制备方法
CN102442991B (zh) * 2010-10-12 2015-03-11 上海睿智化学研究有限公司 一种金雀异黄素维生素b6共晶、其晶体及其制备方法
CN102442989B (zh) * 2010-10-12 2015-04-08 上海睿智化学研究有限公司 一种金雀异黄素盐、其晶体及其制备方法
CN105963246B (zh) * 2016-05-06 2018-12-25 荆楚理工学院 一种染料木素盐口服溶液剂及制备方法和应用
CN105853350A (zh) * 2016-05-24 2016-08-17 荆楚理工学院 一种染料木素溶液及制备方法和应用
CN109666014A (zh) * 2018-12-12 2019-04-23 荆门医药工业技术研究院 一种染料木素衍生物盐的制备方法及其应用
EP4255415A1 (en) 2020-12-03 2023-10-11 Delta 4 GmbH Genistein for use in the treatment of focal segmental glomerulosclerosis (fsgs)
WO2023212130A1 (en) 2022-04-28 2023-11-02 GreenStone Biosciences, Inc. Treatment of the adverse cardiovascular effects of cannabinoids

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
EP0656786B2 (en) 1992-05-19 2014-04-23 Novogen Research Pty Ltd Use of isoflavone phyto-oestrogen extracts of soy or clover
DE4331233A1 (de) * 1993-09-15 1995-03-16 Basf Ag Verfahren zur Herstellung von Hydroxyoxaalkylmelaminen
US5569459A (en) * 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
US5554519A (en) 1995-08-07 1996-09-10 Fermalogic, Inc. Process of preparing genistein
PL179170B1 (pl) * 1995-09-15 2000-07-31 Inst Lekow Nowe zwiazki,pochodne genisteiny PL PL PL PL
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9613455D0 (en) 1996-06-27 1996-08-28 Aston Molecules Ltd Analogues or derivatives of quercetin
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US5981775A (en) 1998-09-16 1999-11-09 Board Of Trustees Operating Michigan State University Process for the preparation of isoflavones
US6194469B1 (en) * 1998-12-11 2001-02-27 Board Of Trustees Operating Michigan State Univeristy Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AUPQ520300A0 (en) * 2000-01-21 2000-02-17 Novogen Research Pty Ltd Food product and process
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
EP1163908B1 (en) 2000-06-16 2004-05-06 Linnea S.A. Water-soluble complex of an extract of Ginkgo Bilboa, process for the preparation thereof and composition comprising the same
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
US6541613B2 (en) * 2000-12-15 2003-04-01 Uyrex Corporation Isoflavone derivatives
PL205635B1 (pl) * 2001-04-09 2010-05-31 Inst Farmaceutyczny Nowe pochodne genisteiny i zawierające je środki farmaceutyczne
CN100348592C (zh) * 2001-12-28 2007-11-14 中国人民解放军第二军医大学 3，7，8－三取代－5－羟基苯并－γ－吡喃酮类化合物及其制备方法
US20040023981A1 (en) 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
SI1578755T1 (sl) 2002-12-24 2007-12-31 Astrazeneca Ab Fosfonooksi kinazolinski derivati in njihova farmacevtska uporaba
JP5017103B2 (ja) * 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
DE602004028113D1 (de) * 2004-07-20 2010-08-26 Furfural Espanol S A Verwendung von 2,3-Dehydronaringenin-Derivaten zur Behandlung von Entzündungsprozessen und diese Derivate enthaltende pharmazeutische Zusammensetzung
US9579303B2 (en) 2005-02-15 2017-02-28 Dsm Ip Assets B.V. Compositions containing polysaccharides
ES2369928T3 (es) * 2005-06-29 2011-12-09 Dsm Ip Assets B.V. Nanopartículas de isoflavonas y su utilización.
JP2009504682A (ja) 2005-08-11 2009-02-05 ザ スクリプス リサーチ インスティテュート トランスサイレチンアミロイドーシスのゲニステインによる阻害
WO2007061254A1 (en) * 2005-11-25 2007-05-31 B & C Biopharm. Co., Ltd. Genistein derivatives and anti-fungal composition containing the same
EP2074223A4 (en) * 2006-09-15 2010-03-10 Foldrx Pharmaceuticals Inc TEST PROCEDURE FOR THE DETECTION OF PROTEINS IN THE NATIVE CONDITION AND FOR THE IDENTIFICATION OF THE STABILITY OF PROTEINS IN THE NATIVE CONDITION MODULATING COMPOUNDS
JP2008094751A (ja) * 2006-10-11 2008-04-24 Ono Pharmaceut Co Ltd プランルカスト水和物含有医薬組成物
EP2373326B1 (en) 2008-12-11 2016-03-09 Axcentua Pharmaceutucals AB Crystalline forms of genistein

Similar Documents

Publication Publication Date Title
JP2015193630A5 (ja)
JP2013237682A5 (ja)
JP2017061566A5 (ja)
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP2017524735A5 (ja)
JP2016515561A5 (ja)
NZ726366A (en) Syk inhibitors
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
TN2015000293A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
JP2015516419A5 (ja)
JP2016503010A5 (ja)
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
JP2012512164A5 (ja)
MX2022001863A (es) Metodos para tratar los tumores del estroma gastrointestinal.
WO2020033838A3 (en) Treatment of egfr-mutant cancer
BR112015016184A2 (pt) derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
JP2013544892A5 (ja)
JP2010500284A5 (ja)
JP2014509637A5 (ja)
MX2015008292A (es) Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
RU2016116955A (ru) Гидробромидная соль n-(4-хлор-2-гидрокси-3-((3s)-3-пиперидинилсульфонил)фенил)-n'-(3-фтор-2-метилфенил)мочевины
JP2016510332A5 (ja)